UBS Adjusts Edwards Lifesciences Price Target to $92 From $84, Maintains Neutral Rating
UBS Adjusts Edwards Lifesciences Price Target to $92 From $84, Maintains Neutral Rating
瑞銀將愛德華茲生命科學的目標股價從84美元調整至92美元，維持中性評級
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊